While I don’t love the Knicks, and I’m annoyed they’re roasting the Spurs, I’m still so so so happy we’re watching this instead of SGA and the Floppettes. #nbafinals
This is WILD. Gene editing just produced a serious clinical result.
Verve Therapeutics (now part of Eli Lilly $LLY) released Phase 1b data on VERVE-102, a one-time IV infusion that uses base editing to permanently switch off the PCSK9 gene in the liver.
The result: up to 62% reduction in LDL cholesterol from a single dose, sustained out to 18 months so far. 35 patients. No serious adverse events.
Today, high cholesterol is managed with a daily statin for life. If this holds up in Phase 2 and 3, the model becomes: one infusion, done.
The GLP-1 comparison gets thrown around. Worth remembering Ozempic was already approved for diabetes when Phase 2 obesity data dropped. VERVE-102 has 35 patients across six dose cohorts. Different risk picture.
Chronic disease management is slowly being replaced by one-shot biological edits. Heart disease still kills more people than anything else. If this works, it's a category change.
Phase 2 starts by year end.
1/5
I'm a cardiologist. I have spent twenty years watching cholesterol destroy arteries, trigger heart attacks, and kill people I care about.
Today, Eli Lilly presented data that may begin to end that era.
VERVE-102. A single infusion. One dose. It uses base editing to permanently turn off the PCSK9 gene in your liver.
Presented today at the European Atherosclerosis Society Congress:
88% reduction in PCSK9.
62% reduction in LDL cholesterol.
Sustained up to 18 months.
No treatment-related serious adverse events.
One infusion. Not daily pills you forget to take. Not monthly injections. One dose — and your cholesterol may stay low for the rest of your life.
@giyu_codes No, the focus of modern IT companies is exclusively recurring revenue. There is an NRR component with one time projects, but the more recurring revenue, the more enterprise value.